Zofran
Prostate Small Cell Neuroendocrine Carcinoma
Fred Hutchinson Cancer CenterPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Prostate Small Cell Neuroendocrine Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PREDNISONE TABLETS Fred Hutchinson Cancer Center | Phase 2 | B |
Abiraterone Acetate University of Washington | Phase 2 | CCC |
Bendamustine Fred Hutchinson Cancer Center | Phase 1 | CC |
PANTOPRAZOLE Fred Hutchinson Cancer Center | Phase 1 | CC |
Cyclophosphamide Fred Hutchinson Cancer Center | Phase 1 | CC |
Fludarabine Fred Hutchinson Cancer Center | Phase 1 | CC |
BROMAZEPAM Fred Hutchinson Cancer Center | Phase 1 | CC |
T-Cell Receptor-Engineered T-Cells Fred Hutchinson Cancer Center | Phase 1 | CC |
Same molecule, other indications
Zofran is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →